Search: onr:"swepub:oai:gup.ub.gu.se/208362" >
Cerebrospinal fluid...
Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.
-
Lleó, Alberto (author)
-
Cavedo, Enrica (author)
-
Parnetti, Lucilla (author)
-
show more...
-
Vanderstichele, Hugo (author)
-
Herukka, Sanna Kaisa (author)
-
- Andreasen, Niels (author)
- Karolinska Institutet
-
Ghidoni, Roberta (author)
-
Lewczuk, Piotr (author)
-
Jeromin, Andreas (author)
-
- Winblad, Bengt (author)
- Karolinska Institutet
-
Tsolaki, Magda (author)
-
Mroczko, Barbara (author)
-
Visser, Pieter Jelle (author)
-
Santana, Isabel (author)
-
- Svenningsson, Per (author)
- Karolinska Institutet
-
- Blennow, Kaj, 1958 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
-
- Aarsland, Dag (author)
- Karolinska Institutet
-
Molinuevo, José Luis (author)
-
- Zetterberg, Henrik, 1973 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
-
Mollenhauer, Brit (author)
-
show less...
-
(creator_code:org_t)
- 2014-12-16
- 2015
- English.
-
In: Nature reviews. Neurology. - : Springer Science and Business Media LLC. - 1759-4766 .- 1759-4758. ; 11, s. 41-55
- Related links:
-
https://gup.ub.gu.se...
-
show more...
-
https://doi.org/10.1...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- Alzheimer disease (AD) and Parkinson disease (PD) are the most common neurodegenerative disorders. For both diseases, early intervention is thought to be essential to the success of disease-modifying treatments. Cerebrospinal fluid (CSF) can reflect some of the pathophysiological changes that occur in the brain, and the number of CSF biomarkers under investigation in neurodegenerative conditions has grown rapidly in the past 20 years. In AD, CSF biomarkers are increasingly being used in clinical practice, and have been incorporated into the majority of clinical trials to demonstrate target engagement, to enrich or stratify patient groups, and to find evidence of disease modification. In PD, CSF biomarkers have not yet reached the clinic, but are being studied in patients with parkinsonism, and are being used in clinical trials either to monitor progression or to demonstrate target engagement and downstream effects of drugs. CSF biomarkers might also serve as surrogate markers of clinical benefit after a specific therapeutic intervention, although additional data are required. It is anticipated that CSF biomarkers will have an important role in trials aimed at disease modification in the near future. In this Review, we provide an overview of CSF biomarkers in AD and PD, and discuss their role in clinical trials.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Neurosciences (hsv//eng)
Publication and Content Type
- ref (subject category)
- for (subject category)
Find in a library
To the university's database
- By the author/editor
-
Lleó, Alberto
-
Cavedo, Enrica
-
Parnetti, Lucill ...
-
Vanderstichele, ...
-
Herukka, Sanna K ...
-
Andreasen, Niels
-
show more...
-
Ghidoni, Roberta
-
Lewczuk, Piotr
-
Jeromin, Andreas
-
Winblad, Bengt
-
Tsolaki, Magda
-
Mroczko, Barbara
-
Visser, Pieter J ...
-
Santana, Isabel
-
Svenningsson, Pe ...
-
Blennow, Kaj, 19 ...
-
Aarsland, Dag
-
Molinuevo, José ...
-
Zetterberg, Henr ...
-
Mollenhauer, Bri ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Basic Medicine
-
and Neurosciences
- Articles in the publication
-
Nature reviews. ...
- By the university
-
University of Gothenburg
-
Karolinska Institutet